<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46813">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01787227</url>
  </required_header>
  <id_info>
    <org_study_id>TDP-736-272</org_study_id>
    <nct_id>NCT01787227</nct_id>
  </id_info>
  <brief_title>A Two Arm, Multi-Centre Clinical Evaluation of the xTAG Respiratory Viral Panel v3 Test</brief_title>
  <official_title>A Two Arm, Multi-Centre Clinical Evaluation of the xTAG Respiratory Viral Panel v3 Test in Patients With Clinical Signs and Symptoms of Respiratory Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luminex Molecular Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luminex Molecular Diagnostics</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      xTAG RVP v3 assay is a PCR-based assay to detect the presence or absence of viral and
      bacterial DNA / RNA in clinical specimens (nasopharyngeal swabs).

      The objective of this study is to establish diagnostic accuracy of the xTAG RVP v3.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Diagnostic accuracy will be expressed in terms of clinical sensitivity and specificity for each claimed target.</measure>
    <time_frame>Within the first year after sample extraction</time_frame>
    <safety_issue>No</safety_issue>
    <description>Accuracy determinations (diagnostic sensitivity and specificity, positive and negative agreement) were based on the fraction of comparator positive (or negative) results which were also positive (or negative) by xTAG RVP v3.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Respiratory Tract Infection</condition>
  <condition>Bronchitis</condition>
  <condition>Bronchiolitis</condition>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Blinded, Pre-selected Arm</arm_group_label>
    <description>For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded, Prospective Arm</arm_group_label>
    <description>Diagnostic accuracy for the more prevalent targets will be evaluated in prospectively collected, de-identified, left-over, clinical specimens accrued during the 2012/2013 flu season.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>xTAG RVP v3</intervention_name>
    <arm_group_label>Blinded, Pre-selected Arm</arm_group_label>
    <arm_group_label>Blinded, Prospective Arm</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasopharyngeal swab
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Clinical specimens collected from patients with clinical signs and symptoms of respiratory
        tract infection who are either hospitalized, admitted to emergency departments or visiting
        outpatient clinics.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The specimen is a nasopharyngeal swab.

          -  The specimen is from a pediatric or adult, male or female subject who is either
             hospitalized, admitted to a hospital emergency department, visiting an outpatient
             clinic or resident of a long-term care facility.

          -  The specimen is from a patient exhibiting clinical signs and symptoms of respiratory
             tract infection such as fever, sore throat, shortness of breath, bronchitis,
             bronchiolitis and pneumonia.

        Exclusion Criteria:

          -  The specimen is not a nasopharyngeal swab.

          -  The specimen is from an individual who does not exhibit clinical signs and symptoms
             of respiratory tract infection.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Liu, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Luminex Molecular Diagnostics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Mahony, Ph.D, FCCM, FAAM</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Health Care London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Buller, PhD, D (ABMM)</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arundhati Rao, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scott and White Hospital &amp; Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Ginocchio, Ph.D., M.T.(A.S.C.P.)</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Shore‐LIJ Health System Laboratories, NY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Buller</last_name>
      <email>Buller@kids.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Buller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore‐LIJ Health System Laboratories</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Manji</last_name>
      <email>rmanji@nshs.edu</email>
    </contact>
    <investigator>
      <last_name>Christine Ginocchio, Ph.D., M.T. (ASCP)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Amlin</last_name>
      <email>tamlin@swmail.sw.org</email>
    </contact>
    <investigator>
      <last_name>Arundhati Rao, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Chong</last_name>
      <email>sylviachong3@gmail.com</email>
    </contact>
    <investigator>
      <last_name>James Mahony, Ph.D., FCCM, FAAM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>February 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
